On the stock market since 2014, it operates in the world of health and science. It has 2,495 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 34% below its peak. The market has trimmed its expectations for the company.
It pays out $0.05 per share each year — regular cash for whoever holds the stock.
A loss of $70.7M against $648.7M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, BIESF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BIESF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.